A phase 1, randomised, single-centre, double-blind, single-dose, two period balanced cross
over study in a glucose clamp setting. The study compares the pharmacodynamic,
pharmacokinetic and safety characteristics of AT278 and NovoRapid® in male participants with
type 1 diabetes.